Diverse roles of ANGPTL2 in physiology and pathophysiology

Trends in Endocrinology and Metabolism

Volumn 25, Issue 5, 2014, Pages 245-254

  Kadomatsu, Tsuyoshi ^a   Endo, Motoyoshi ^a   Miyata, Keishi ^a   Oike, Yuichi ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Angiopoietin like protein 2; Chronic inflammation; Circadian rhythm; Lifestyle disease; Tissue remodeling; Tissue repair

Indexed keywords

ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN; INTEGRIN;

ANIMAL; ATHEROSCLEROSIS; HUMAN; INFLAMMATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOPOIETINS; ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84899490176     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.03.012     Document Type: Review

References (71)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
2. Handschin C., Spiegelman B.M. The role of exercise and PGC1α in inflammation and chronic disease. Nature 2008, 454:463-469.
3. Yancopoulos G.D., et al. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
4. Hato T., et al. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc. Med. 2008, 18:6-14.
5. Kim I., et al. Molecular cloning, expression, and characterization of angiopoietin-related protein induces endothelial cell sprouting. J. Biol. Chem. 1999, 274:26523-26528.
6. Mattijssen F., Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim. Biophys. Acta 2012, 1821:782-789.
7. Oike Y., et al. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol. Med. 2005, 11:473-479.
8. Oike Y., et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat. Med. 2005, 11:400-408.
9. Wang Y., et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16109-16114.
10. Yi P., et al. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013, 153:747-758.
11. Tabata M., et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009, 10:178-188.
12. Kubota Y., et al. Isolation and expression patterns of genes for three angiopoietin-like proteins, Angptl1, 2 and 6 in zebrafish. Gene Expr. Patterns 2005, 5:679-685.
13. Horio E., et al. The role of endothelial cell-derived ANGPTL2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler. Thromb. Vasc. Biol. 2014, 34:790-800.
14. Aoi J., et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res. 2011, 71:7502-7512.
15. Endo M., et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res. 2012, 72:1784-1794.
16. Odagiri H., et al. The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin α5β1, p38MAPK, and matrix metalloproteinases. Sci. Signal. 2014, 7:ra7.
17. Oike Y., Tabata M. Angiopoietin-like proteins - potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ. J. 2009, 73:2192-2197.
18. Kubota Y., et al. Cooperative interaction of angiopoietin-like proteins 1 and 2 in zebrafish vascular development. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13502-13507.
19. Dhanabal M., et al. Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties. Biochem. Biophys. Res. Commun. 2005, 333:308-315.
20. Dhanabal M., et al. Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. Cancer Res. 2002, 62:3834-3841.
21. Oike Y., et al. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int. J. Hematol. 2004, 80:21-28.
22. Akimenko M.A., et al. Old questions, new tools, and some answers to the mystery of fin regeneration. Dev. Dyn. 2003, 226:190-201.
23. Gill S.E., Parks W.C. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 2008, 40:1334-1347.
24. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000, 14:2123-2133.
25. Bai S., et al. Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2. Matrix Biol. 2005, 24:247-260.
26. Tazume H., et al. Macrophage-derived angiopoietin-like protein 2 accelerates development of abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1400-1409.
27. Sun K., et al. Adipose tissue remodeling and obesity. J. Clin. Invest. 2011, 121:2094-2101.
28. Doi Y., et al. Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care 2013, 36:98-100.
29. Muramoto A., et al. Angiopoietin-like protein 2 sensitively responds to weight reduction induced by lifestyle intervention on overweight Japanese men. Nutr. Diabetes 2011, 1:e20.
30. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
31. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
32. Aghamohammadzadeh R., et al. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br. J. Pharmacol. 2012, 165:670-682.
33. Takaoka M., et al. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ. Res. 2009, 105:906-911.
34. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
35. Tian Z., et al. Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury. J. Mol. Cell. Cardiol. 2013, 57:1-12.
36. Rizas K.D., et al. Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol. Rev. 2009, 17:201-210.
37. Shimizu K., et al. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2006, 26:987-994.
38. Longo G.M., et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 2002, 110:625-632.
39. Farhat N., et al. Angiopoietin-like 2 promotes atherogenesis in mice. J. Am. Heart Assoc. 2013, 2:e000201.
40. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
41. Yuspa S.H. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J. Dermatol. Sci. 1998, 17:1-7.
42. Aoi J., et al. Angiopoietin-like protein 2 accelerates carcinogenesis by activating chronic inflammation and oxidative stress. Mol. Cancer Res. 2013, 12:239-249.
43. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
44. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8:705-713.
45. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9:285-293.
46. Vlahopoulos S.A., et al. The role of ATF-2 in oncogenesis. Bioessays 2008, 30:314-327.
47. Kikuchi R., et al. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res. 2008, 68:5067-5075.
48. Endo M., et al. Serum ANGPTL2 levels reflect clinical features of breast cancer patients: implications for the pathogenesis of breast cancer metastasis. Int. J. Biol. Markers 2014, 10.5301/jbm.5000080.
49. Ohnishi J., et al. Functions for proteinases in the ovulatory process. Biochim. Biophys. Acta 2005, 1751:95-109.
50. Berry R., et al. Structural and functional evidence for a substrate exclusion mechanism in mammalian tolloid like-1 (TLL-1) proteinase. FEBS Lett. 2010, 584:657-661.
51. Clark T.G., et al. The mammalian Tolloid-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Development 1999, 126:2631-2642.
52. Hagihara A., et al. Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004, 23:8705-8710.
53. Cresci S., et al. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation 2011, 124:1426-1434.
54. Kadomatsu T., et al. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011, 278:559-564.
55. Bass J., Takahashi J.S. Circadian integration of metabolism and energetics. Science 2010, 330:1349-1354.
56. Curtis A.M., et al. Circadian clock proteins and immunity. Immunity 2014, 40:178-186.
57. Green C.B., et al. The meter of metabolism. Cell 2008, 134:728-742.
58. Ukai H., Ueda H.R. Systems biology of mammalian circadian clocks. Annu. Rev. Physiol. 2010, 72:579-603.
59. Bass J. Circadian topology of metabolism. Nature 2012, 491:348-356.
60. Takahashi J.S., et al. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 2008, 9:764-775.
61. Kitazawa M., et al. Angiopoietin-like 2, a circadian gene, improves type 2 diabetes through potentiation of insulin sensitivity in mice adipocytes. Endocrinology 2011, 152:2558-2567.
62. Kadomatsu T., et al. A molecular clock regulates angiopoietin-like protein 2 expression. PLoS ONE 2013, 8:e57921.
63. Zhang C.C., et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat. Med. 2006, 12:240-245.
64. Blery M., et al. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:2446-2451.
65. Martin A.M., et al. Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol. 2002, 23:81-88.
66. Zheng J., et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 2012, 485:656-660.
67. Takai T., Ono M. Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol. Rev. 2001, 181:215-222.
68. Guo D.F., et al. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem. Biophys. Res. Commun. 2003, 310:1254-1265.
69. Mederle K., et al. The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension. Crit. Care 2013, 17:R130.
70. Ge H., et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J. Biol. Chem. 2004, 279:2038-2045.
71. Ono M., et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J. Biol. Chem. 2003, 278:41804-41809.